ABSTRACT
BACKGROUND: CD276 is an immune checkpoint molecule. Elevated CD276 expression by urothelial carcinoma is associated with poor prognosis, but little is known about its expression across different tumor stages. We therefore investigated CD276 expression in bladder cancer (BC) cells and in tissue samples of BC stages from pT2 to pT4. METHODS: CD276 expression was explored in 4 urothelial cancer cell lines and 4 primary normal urothelial cell populations by quantitative RT-PCR, Western blot and flow cytometry. CD276 was investigated in bladder tumors from 98 patients by immunohistochemistry using a score (0-300) incorporating both, staining intensity and area of CD276 staining. Normal appearing urothelium in the bladder of the same patients served as controls. RESULTS: The urothelial carcinoma cell lines expressed significantly higher levels of CD276 on transcript (p < 0.006), total protein levels (p < 0.005), and on the cell surface (p < 0.02) when compared to normal urothelial cells. In pT2-T4 tumor tissue samples, CD276 was overexpressed (median score 185) when compared to corresponding healthy tissues from the same patients (median score 50; p < 0.001). No significant differences in CD276 expression were recorded in late, locally advanced ≥ pT3a tumors (median score 185) versus organ-confined < pT3a tumors (median score 190), but it was significantly lower in the normal urothelial tissue associated with ≥ pT3a tumors (median score 40) versus < pT3a tumors (median score 80; p < 0.05). CONCLUSION: CD276 expression is significantly elevated in urothelial carcinoma cells in all stages but varies between individuals considerably. Reduced CD276 expression in normal urothelial cells may imply that these cells would be protected from CD276-mediated immuno therapies.
Subject(s)
B7 Antigens/genetics , Carcinoma, Transitional Cell/genetics , Gene Expression Regulation, Neoplastic , Urinary Bladder Neoplasms/genetics , Adult , Aged , Aged, 80 and over , B7 Antigens/analysis , Carcinoma, Transitional Cell/chemistry , Carcinoma, Transitional Cell/pathology , Cell Line, Tumor , Female , Humans , Male , Middle Aged , Neoplasm Staging , Urinary Bladder Neoplasms/chemistry , Urinary Bladder Neoplasms/pathologyABSTRACT
BACKGROUND: Although guidelines exist for advanced and variant bladder cancer management, evidence is limited/conflicting in some areas and the optimal approach remains controversial. OBJECTIVE: To bring together a large multidisciplinary group of experts to develop consensus statements on controversial topics in bladder cancer management. DESIGN: A steering committee compiled proposed statements regarding advanced and variant bladder cancer management which were assessed by 113 experts in a Delphi survey. Statements not reaching consensus were reviewed; those prioritised were revised by a panel of 45 experts before voting during a consensus conference. SETTING: Online Delphi survey and consensus conference. PARTICIPANTS: The European Association of Urology (EAU), the European Society for Medical Oncology (ESMO), experts in bladder cancer management. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Statements were ranked by experts according to their level of agreement: 1-3 (disagree), 4-6 (equivocal), 7-9 (agree). A priori (level 1) consensus was defined as ≥70% agreement and ≤15% disagreement, or vice versa. In the Delphi survey, a second analysis was restricted to stakeholder group(s) considered to have adequate expertise relating to each statement (to achieve level 2 consensus). RESULTS AND LIMITATIONS: Overall, 116 statements were included in the Delphi survey. Of these, 33 (28%) statements achieved level 1 consensus and 49 (42%) statements achieved level 1 or 2 consensus. At the consensus conference, 22 of 27 (81%) statements achieved consensus. These consensus statements provide further guidance across a broad range of topics, including the management of variant histologies, the role/limitations of prognostic biomarkers in clinical decision making, bladder preservation strategies, modern radiotherapy techniques, the management of oligometastatic disease and the evolving role of checkpoint inhibitor therapy in metastatic disease. CONCLUSIONS: These consensus statements provide further guidance on controversial topics in advanced and variant bladder cancer management until a time where further evidence is available to guide our approach.
Subject(s)
Consensus , Medical Oncology/standards , Practice Guidelines as Topic , Urinary Bladder Neoplasms/therapy , Urology/standards , Delphi Technique , Europe , Humans , International Cooperation , Medical Oncology/methods , Neoplasm Staging , Societies, Medical/standards , Stakeholder Participation , Surveys and Questionnaires , Urinary Bladder/pathology , Urinary Bladder Neoplasms/pathology , Urology/methodsABSTRACT
BACKGROUND: Cisplatin-based neoadjuvant chemotherapy (NAC) for muscle invasive bladder cancer improves all-cause and cancer specific survival. We aimed to evaluate whether the detection of carcinoma in situ (CIS) at the time of initial transurethral resection of bladder tumor (TURBT) has an oncological impact on the response to NAC prior to radical cystectomy. PATIENTS AND METHODS: Patients were identified retrospectively from 19 centers who received at least three cycles of NAC or induction chemotherapy for cT2-T4aN0-3M0 urothelial carcinoma of the bladder followed by radical cystectomy between 2000 and 2013. The primary and secondary outcomes were pathological response and overall survival, respectively. Multivariable analysis was performed to determine the independent predictive value of CIS on these outcomes. RESULTS: Of 1213 patients included in the analysis, 21.8% had concomitant CIS. Baseline clinical and pathologic characteristics of the 'CIS' versus 'no-CIS' groups were similar. The pathological response did not differ between the two arms when response was defined as pT0N0 (17.9% with CIS vs 21.9% without CIS; p = 0.16) which may indicate that patients with CIS may be less sensitive to NAC or ≤ pT1N0 (42.8% with CIS vs 37.8% without CIS; p = 0.15). On Cox regression model for overall survival for the cN0 cohort, the presence of CIS was not associated with survival (HR 0.86 (95% CI 0.63-1.18; p = 0.35). The presence of LVI (HR 1.41, 95% CI 1.01-1.96; p = 0.04), hydronephrosis (HR 1.63, 95% CI 1.23-2.16; p = 0.001) and use of chemotherapy other than ddMVAC (HR 0.57, 95% CI 0.34-0.94; p = 0.03) were associated with shorter overall survival. For the whole cohort, the presence of CIS was also not associated with survival (HR 1.05 (95% CI 0.82-1.35; p = 0.70). CONCLUSION: In this multicenter, real-world cohort, CIS status at TURBT did not affect pathologic response to neoadjuvant or induction chemotherapy. This study is limited by its retrospective nature as well as variability in chemotherapy regimens and surveillance regimens.
Subject(s)
Antineoplastic Agents/therapeutic use , Carcinoma in Situ/therapy , Cystectomy , Induction Chemotherapy , Neoadjuvant Therapy , Urinary Bladder Neoplasms/therapy , Aged , Carcinoma in Situ/mortality , Carcinoma in Situ/pathology , Cisplatin/therapeutic use , Female , Humans , Male , Middle Aged , Retrospective Studies , Survival Rate , Treatment Outcome , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathologyABSTRACT
Social instability occurs as a consequence of war, civil strife or natural disasters such as earthquakes, floods and droughts. Animal diseases, including zoonoses, can be both a precursor to social instability and a result of social instability. Coping mechanisms, such as sound policies, trust in government, and robust infrastructure break down at times of civil instability. Such breakdowns often lead to a decline in both public health and the food and agricultural livestock base, thus creating a vicious cycle that involves inadequate nutrition, threatened livelihoods, and fewer opportunities for safe trade. This article is principally a discussion of a theoretical nature on the dynamics between animal diseases and social instability. Based on their experience of working for the Food and Agriculture Organization of the United Nations (FAO), the authors provide numerous examples of the connection between the two, mostly in countries that have fragile environments and are experiencing protracted crises. Disease has a direct and immediate effect on a community, but, in addition, if the community is not able to recover from the impact of a disease on their health and livelihoods, the consequences of an outbreak can persist even after the disease is no longer present. Stability, therefore, depends on a variety of factors, including the ability of a community to overcome the effects of a disease outbreak or other destabilising event. The FAO approach to helping families and communities to cope with the destabilizing effects of animal diseases is to build resilience, particularly amongst the most vulnerable households. This requires individuals and governments to gain a better understanding of what drives disease at the interface between human and animal health. In addition, it requires governments to invest in social protection programmes, establish a long-term risk reduction strategy that decreases vulnerability, and improve the sustainability of safe agricultural and marketing practices.
L'instabilité sociale est généralement une conséquence des conflits armés, des guerres civiles ou des catastrophes naturelles telles que tremblements de terre, inondations ou sécheresse. Les maladies animales, zoonoses incluses, sont des signes précurseurs de l'instabilité sociale, mais aussi son résultat. En période d'instabilité sociale, les mécanismes d'adaptation aux crises liés notamment à des politiques judicieuses, à la confiance dans l'action du gouvernement et à des infrastructures solides s'effondrent. Ces défaillances entraînent souvent un déclin à la fois de la santé publique et des ressources essentielles de l'agriculture et de l'élevage, créant ainsi un cercle vicieux caractérisé par une nutrition inadéquate, des moyens d'existence menacés et des possibilités raréfiées d'accéder à des marchés sûrs. L'essentiel de cet article est consacré à l'analyse théorique de la dynamique des liens entre les maladies animales et l'instabilité sociale. À partir de l'expérience acquise en travaillant pour l'Organisation des Nations Unies pour l'alimentation et l'agriculture (FAO), les auteurs donnent de nombreux exemples de ces liens, qui concernent pour la plupart des pays dont l'environnement est fragilisé ou qui sont exposés à des crises prolongées. Toute maladie a un effet direct et immédiat sur la communauté atteinte ; or, dans les situations où une communauté n'est pas en capacité de se relever après avoir subi cet impact ni d'assurer un retour à la situation antérieure en matière de santé et de moyens de subsistance, les conséquences d'un foyer persistent bien au-delà de la durée de la maladie. Par conséquent, la stabilité dépend de facteurs variés, dont l'aptitude d'une communauté à surmonter les effets d'un foyer ou d'autres événements déstabilisants. La méthode suivie par la FAO pour aider les familles et les communautés à faire face aux effets déstabilisants des maladies animales consiste à renforcer leur capacité de résilience, en particulier dans les foyers les plus vulnérables. Cela suppose que les individus et les gouvernements améliorent leur connaissance des facteurs propices à l'apparition des maladies à l'interface entre la santé humaine et animale. En outre, cela suppose que les gouvernements investissent dans des programmes de protection sociale, qu'ils mettent en place une stratégie de réduction des risques sur le long terme qui limite les vulnérabilités et qu'ils Åuvrent pour une meilleure durabilité des pratiques agricoles et commerciales exemptes de risques.
La inestabilidad social es producto de guerras, disturbios civiles o catástrofes naturales como terremotos, inundaciones o sequías. Las enfermedades animales, comprendidas las zoonosis, pueden ser un precursor o un resultado de la inestabilidad social. En condiciones de inestabilidad civil se agrietan los mecanismos de un país para hacer frente a esas enfermedades (tales como políticas sólidas, confianza en los poderes públicos e infraestructuras robustas), lo que suele traducirse en un deterioro de la salud pública y de la cabaña ganadera en que reposan la alimentación y la agricultura, generándose así un círculo vicioso que trae consigo una nutrición deficiente, pone en peligro los medios de sustento y dificulta un comercio seguro. Los autores examinan básicamente los aspectos teóricos de la dinámica que conecta entre sí las enfermedades animales y la inestabilidad social. Recurriendo a su experiencia de trabajo para la Organización de las Naciones Unidas para la Alimentación y la Agricultura (FAO), ofrecen numerosos ejemplos de la relación existente entre ambos fenómenos, sobre todo en países que presentan un medio ambiente fragilizado y sufren crisis prolongadas. La enfermedad repercute directa e inmediatamente en la población, pero además, si esta no puede recuperarse de los efectos de una enfermedad sobre su estado sanitario y sus medios de vida, las consecuencias de un brote pueden dejarse sentir hasta mucho después de que la enfermedad haya desaparecido. La estabilidad depende por lo tanto de diversos factores, en particular la capacidad de las comunidades para superar los efectos de un brote infeccioso u otros episodios que las hayan desestabilizado. Desde la FAO se trata de ayudar a las familias y comunidades a lidiar con los efectos desestabilizadores de las enfermedades animales generando resiliencia, especialmente en las familias más vulnerables. Para ello es menester que tanto individuos como poderes públicos conozcan mejor los factores que hacen que una enfermedad se manifieste en la interfaz de la salud humana con la sanidad animal. Es preciso, además, que las administraciones inviertan en programas de protección social, instituyan una estrategia a largo plazo de reducción del riesgo, que redunde en una menor vulnerabilidad, e instauren procedimientos agrícolas y de comercialización más sostenibles.
Subject(s)
Animal Diseases/economics , Animal Diseases/epidemiology , Epidemics/veterinary , Social Conditions , Animals , Global Health , HumansABSTRACT
PURPOSE: The optimal extent of pelvic lymph node dissection (PLND) during radical cystectomy (RC) in patients with urothelial carcinoma of the bladder (UCB) is the subject of ongoing debate. In this study, we compared local recurrence-free and overall survival, in addition to complication rates, after extended PLND (ePLND) compared to standard PLND (sPLND). METHODS: We reviewed the charts of 314 patients who underwent RC for UCB between 2008 and 2013. ePLND was performed in 105 patients, and 105 matched patients who underwent standard PLND (sPLND) were selected based on clinical parameters. Local recurrence-free and overall survival rates were assessed using Kaplan-Meier survival analysis, and Cox proportional hazards models were used to assess potential determinants of these outcomes. Complications were assessed at 30 and 90 days using the Clavien-Dindo reporting system. RESULTS: More lymph nodes were removed by ePLND (median 21) compared to sPLND (median 9; P < 0.001), but the rate of nodal involvement was not different. In multivariable analysis, ePLND was associated with a better local recurrence-free survival (HR = 0.63, P = 0.005), but was not an independent predictor of overall survival (HR = 1.06, P = 0.84). Estimated blood loss was greater with ePLND (1047.3 vs. 584.5 ml P < 0.001), but there was no significant difference in complications. CONCLUSIONS: Extended PLND appears to reduce the risk of local recurrence, but was not an independent predictor of overall survival in this cohort. ePLND was associated with greater blood loss compared to sPLND, but not with other perioperative complications.
Subject(s)
Carcinoma, Transitional Cell/surgery , Cystectomy/methods , Lymph Node Excision/methods , Urinary Bladder Neoplasms/surgery , Aged , Blood Loss, Surgical , Carcinoma, Transitional Cell/mortality , Carcinoma, Transitional Cell/pathology , Case-Control Studies , Cohort Studies , Disease-Free Survival , Female , Humans , Kaplan-Meier Estimate , Lymph Nodes/pathology , Male , Middle Aged , Multivariate Analysis , Pelvis , Prognosis , Proportional Hazards Models , Retrospective Studies , Risk Assessment , Survival Rate , Urinary Bladder Neoplasms/mortality , Urinary Bladder Neoplasms/pathologyABSTRACT
BACKGROUND: Whole genome sequencing has revolutionised the interrogation of mycobacterial genomes. Recent studies have reported conflicting findings on the genomic stability of Mycobacterium tuberculosis during the evolution of drug resistance. In an age where whole genome sequencing is increasingly relied upon for defining the structure of bacterial genomes, it is important to investigate the reliability of next generation sequencing to identify clonal variants present in a minor percentage of the population. This study aimed to define a reliable cut-off for identification of low frequency sequence variants and to subsequently investigate genetic heterogeneity and the evolution of drug resistance in M. tuberculosis. METHODS: Genomic DNA was isolated from single colonies from 14 rifampicin mono-resistant M. tuberculosis isolates, as well as the primary cultures and follow up MDR cultures from two of these patients. The whole genomes of the M. tuberculosis isolates were sequenced using either the Illumina MiSeq or Illumina HiSeq platforms. Sequences were analysed with an in-house pipeline. RESULTS: Using next-generation sequencing in combination with Sanger sequencing and statistical analysis we defined a read frequency cut-off of 30% to identify low frequency M. tuberculosis variants with high confidence. Using this cut-off we demonstrated a high rate of genetic diversity between single colonies isolated from one population, showing that by using the current sequencing technology, single colonies are not a true reflection of the genetic diversity within a whole population and vice versa. We further showed that numerous heterogeneous variants emerge and then disappear during the evolution of isoniazid resistance within individual patients. Our findings allowed us to formulate a model for the selective bottleneck which occurs during the course of infection, acting as a genomic purification event. CONCLUSIONS: Our study demonstrated true levels of genetic diversity within an M. tuberculosis population and showed that genetic diversity may be re-defined when a selective pressure, such as drug exposure, is imposed on M. tuberculosis populations during the course of infection. This suggests that the genome of M. tuberculosis is more dynamic than previously thought, suggesting preparedness to respond to a changing environment.
Subject(s)
Genetic Heterogeneity , Genome, Bacterial , High-Throughput Nucleotide Sequencing , Mycobacterium tuberculosis/genetics , Antitubercular Agents/pharmacology , Drug Resistance, Bacterial , Evolution, Molecular , Genetic Variation , Genomics/methods , Humans , Mycobacterium tuberculosis/drug effects , Mycobacterium tuberculosis/isolation & purification , ROC Curve , Sequence Analysis, DNA , Tuberculosis, Pulmonary/drug therapy , Tuberculosis, Pulmonary/microbiologyABSTRACT
Emerging and re-emerging infectious disease (EID) events can have devastating human, animal and environmental health impacts. The emergence of EIDs has been associated with interconnected economic, social and environmental changes. Understanding these changes is crucial for EID preparedness and subsequent prevention and control of EID events. The aim of this review is to describe tools currently available for identification, prioritization and investigation of EIDs impacting human and animal health, and how these might be integrated into a systematic approach for directing EID preparedness. Environmental scanning, foresight programmes, horizon scanning and surveillance are used to collect and assess information for rapidly responding to EIDs and to anticipate drivers of emergence for mitigating future EID impacts. Prioritization of EIDs - using transparent and repeatable methods - based on disease impacts and the importance of those impacts to decision-makers can then be used for more efficient resource allocation for prevention and control. Risk assessment and simulation modelling methods assess the likelihood of EIDs occurring, define impact and identify mitigation strategies. Each of these tools has a role to play individually; however, we propose integration of these tools into a framework that enhances the development of tactical and strategic plans for emerging risk preparedness.
Subject(s)
Civil Defense , Communicable Disease Control/methods , Communicable Diseases, Emerging/diagnosis , Communicable Diseases, Emerging/therapy , Disease Transmission, Infectious/prevention & control , Emergency Medicine/methods , Animals , Communicable Diseases, Emerging/prevention & control , Communicable Diseases, Emerging/veterinary , Humans , Sentinel Surveillance , Veterinary Medicine/methodsABSTRACT
X-ray backscatter imaging can be used for a wide range of imaging applications, in particular for industrial inspection and portal security. Currently, the application of this imaging technique to the detection of landmines is limited due to the surrounding sand or soil strongly attenuating the 10s to 100s of keV X-rays required for backscatter imaging. Here, we introduce a new approach involving a 140 MeV short-pulse (< 100 fs) electron beam generated by laser wakefield acceleration to probe the sample, which produces Bremsstrahlung X-rays within the sample enabling greater depths to be imaged. A variety of detector and scintillator configurations are examined, with the best time response seen from an absorptive coated BaF2 scintillator with a bandpass filter to remove the slow scintillation emission components. An X-ray backscatter image of an array of different density and atomic number items is demonstrated. The use of a compact laser wakefield accelerator to generate the electron source, combined with the rapid development of more compact, efficient and higher repetition rate high power laser systems will make this system feasible for applications in the field. Content includes material subject to Dstl (c) Crown copyright (2014). Licensed under the terms of the Open Government Licence except where otherwise stated. To view this licence, visit http://www.nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@ nationalarchives.gsi.gov.uk.
Subject(s)
Bombs/classification , Lasers , Radiographic Image Enhancement/instrumentation , Scattering, Radiation , Tomography, X-Ray Computed/instrumentation , Warfare , Equipment Design , Equipment Failure Analysis , Phantoms, Imaging , X-RaysABSTRACT
The One Health movement, as defined in this paper, has progressed from a focus on emerging infectious diseases to a broader set of challenges that include food security and food safety. These interact with climate change, a so-called 'wicked problem' that has links to all human activity. Climate change acts as a threat multiplier that interacts both directly and indirectly with variables, such as disease, food production, food security, food safety and poverty. A number of these interactions are briefly described in this paper before issues of complexity and interconnectedness between these variables are discussed. A common thread underpinning this current global challenge to civilisation is that the system is now dominated by the activities of humans--and many scientists label the current epoch the 'Anthropocene'. Specifically, humans have for the first time collectively overloaded the Earth's capacity to supply, absorb, replenish and stabilise. Many scientists now observe that the ecological and environmental foundations of civilisation appear to be at risk. This paper suggests that, for the One Health movement to address such challenges, the range and number of disciplines that need to be involved must be expanded. In particular, in addition to the insights provided by technical specialists, we need to engage disciplines with the capacity to advance political, economic and social reforms. This will not be easy, but it is argued that this is what is required from the One Health movement in a world with climate change.
Subject(s)
Climate Change , Global Health , Internationality , Animals , Communicable Disease Control , Food Supply , Foodborne Diseases , Humans , ZoonosesABSTRACT
Rifampin resistance in clinical isolates of Mycobacterium tuberculosis arises primarily through the selection of bacterial variants harboring mutations in the 81-bp rifampin resistance-determining region of the rpoB gene. While these mutations were shown to infer a fitness cost in the absence of antibiotic pressure, compensatory mutations in rpoA and rpoC were identified which restore the fitness of rifampin-resistant bacteria carrying mutations in rpoB. To investigate the epidemiological relevance of these compensatory mutations, we analyzed 286 drug-resistant and 54 drug-susceptible clinical M. tuberculosis isolates from the Western Cape, South Africa, a high-incidence setting of multidrug-resistant tuberculosis. Sequencing of a portion of the RpoA-RpoC interaction region of the rpoC gene revealed that 23.5% of all rifampin-resistant isolates tested carried a nonsynonymous mutation in this region. These putative compensatory mutations in rpoC were associated with transmission, as 30.8% of all rifampin-resistant isolates with an IS6110 restriction fragment length polymorphism (RFLP) pattern belonging to a recognized RFLP cluster harbored putative rpoC mutations. Such mutations were present in only 9.4% of rifampin-resistant isolates with unique RFLP patterns (P < 0.01). Moreover, these putative compensatory mutations were associated with specific strain genotypes and the rpoB S531L rifampin resistance mutation. Among isolates harboring this rpoB mutation, 44.1% also harbored rpoC mutations, while only 4.1% of the isolates with other rpoB mutations exhibited mutations in rpoC (P < 0.001). Our study supports a role for rpoC mutations in the transmission of multidrug-resistant tuberculosis and illustrates how epistatic interactions between drug resistance-conferring mutations, compensatory mutations, and different strain genetic backgrounds might influence compensatory evolution in drug-resistant M. tuberculosis.
Subject(s)
Anti-Bacterial Agents/pharmacology , DNA-Directed RNA Polymerases/genetics , Mycobacterium tuberculosis/drug effects , Rifampin/pharmacology , Tuberculosis, Multidrug-Resistant/genetics , Bacterial Proteins/genetics , Base Sequence , Drug Resistance, Bacterial/genetics , Genotype , Humans , Microbial Sensitivity Tests , Mutation , Mycobacterium tuberculosis/genetics , Mycobacterium tuberculosis/isolation & purification , Polymorphism, Restriction Fragment Length/genetics , Sequence Analysis, DNA , Tuberculosis/microbiologyABSTRACT
BACKGROUND: The role of probiotics in prevention of allergic disease is still not clear; efficacy may depend on the timing, dose, duration, and specific probiotic used. Using a double-blind randomized placebo-controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high-risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation from birth until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 × 10(9) cfu/day) halved the cumulative prevalence of eczema at 2 and 4 years. Bifidobacterium animalis subsp lactis HN019 (HN019) (9 × 10(9) cfu/day) had no significant effect. OBJECTIVE: To determine whether differences in effects of HN001 and HN019 on eczema persist to age 6 years, and to investigate effects on sensitization. METHODS: Standard procedures were used to assess eczema (The UK Working Party's Criteria), eczema severity (SCORAD), atopic sensitization [skin prick tests (SPT), total and specific IgE] and standard questions used for asthma, wheeze, and rhinoconjunctivitis. RESULTS: HN001 was associated with significantly lower cumulative prevalence of eczema (HR = 0.56, 95% CI 0.39-0.80), SCORAD ≥ 10 (HR = 0.69, 0.49-0.98) and SPT sensitization (HR = 0.69, 95% CI 0.48-0.99). The point prevalence of eczema (RR = 0.66, 95% CI 0.44-1.00), SCORAD ≥ 10 (RR = 0.62, 95% CI 0.38-1.01) and SPT sensitization (RR = 0.72, 95% CI 0.53-1.00) were also reduced among children taking HN001. HN019 had no significant effect on any outcome. CONCLUSION AND CLINICAL RELEVANCE: This study provides evidence for the efficacy of the probiotic L. rhamnosus HN001 in preventing the development of eczema and possibly also atopic sensitization in high risk infants to age 6 years. The absence of a similar effect for HN019 indicates that benefits may be species specific.
Subject(s)
Dietary Supplements , Eczema/epidemiology , Eczema/prevention & control , Lacticaseibacillus rhamnosus/immunology , Probiotics/therapeutic use , Age Factors , Child , Child, Preschool , Humans , Hypersensitivity, Immediate/prevention & control , Infant , New Zealand/epidemiology , Prevalence , Proportional Hazards Models , Risk , Skin TestsABSTRACT
BACKGROUND: Beta-agonist overuse is associated with adverse outcomes in asthma, however, the relationships between different metrics of salbutamol use and future risk are uncertain. OBJECTIVE: To investigate the relationship between metrics of salbutamol use and adverse outcome. METHODS: In a 24-week randomized controlled trial of 303 asthma patients at risk of severe exacerbations which compared the efficacy and safety of combination budesonide/formoterol inhaler according to a single inhaler regimen (SMART) with a fixed-dose regimen with salbutamol as reliever ('Standard'), actual medication use was measured by electronic monitoring (Australian New Zealand Clinical Trials Registry Number ACTRN12610000515099). A nested cohort study explored the relationship between metrics of baseline salbutamol use over 2 weeks and future severe asthma exacerbations, poor asthma control (ACQ-5 ≥ 1.5) or 'extreme' salbutamol overuse (> 32 salbutamol actuations/24-h period). RESULTS: Higher mean daily salbutamol use (per two actuations/day) [Odds ratio (OR) (95% CI) 1.24 (1.06-1.46)], higher days of salbutamol use (per 2 days in 2 weeks) [OR 1.15 (1.00-1.31)] and higher maximal 24-h use (per two actuations/day) [OR 1.09 (1.02-1.16)] were associated with future severe exacerbations. Higher mean daily salbutamol use was associated with future poor asthma control [OR 1.13 (1.02-1.26)]. Higher mean daily salbutamol use [OR 2.73 (1.84-4.07)], number of days of use [OR 1.46 (1.24-1.71)], and maximal daily use [OR 1.57 (1.31-1.89)] were associated with an increased risk of future extreme salbutamol overuse. CONCLUSION AND CLINICAL RELEVANCE: Electronically recorded frequency of current salbutamol use is a strong predictor of risk of future adverse outcomes in asthma, with average daily use performing the best. These findings provide new information for clinicians considering metrics of salbutamol as predictors of future adverse outcomes in asthma.
Subject(s)
Adrenergic beta-2 Receptor Agonists/therapeutic use , Albuterol/therapeutic use , Asthma/drug therapy , Adrenergic beta-2 Receptor Agonists/administration & dosage , Adrenergic beta-2 Receptor Agonists/adverse effects , Adult , Albuterol/administration & dosage , Albuterol/adverse effects , Drug Overdose , Female , Humans , Male , Middle Aged , Odds Ratio , Prognosis , Risk Factors , Time Factors , Treatment OutcomeABSTRACT
Bacillus Calmette-Guerin (BCG) remains the only FDA-approved first-line therapy in patients with high-risk non-muscle invasive bladder cancer. Recurrences, even after adequate BCG therapy, are common and the efficacy of second-line therapies remains modest. Therefore, early identification of patients likely to recur and treatment after recurrence remain critical unmet needs in the clinical care of bladder cancer patients. To address these deficits, a better understanding of the mechanisms of resistance to BCG-therapy is needed. The virtual update of the International Bladder Cancer Network (IBCN) on the biology of response to BCG focused on potential mechanisms and markers of resistance to intravesical BCG therapy. The insights from this meeting will be highlighted and put into context of previously reported mechanisms of resistance to BCG in this review.
Subject(s)
Non-Muscle Invasive Bladder Neoplasms , Urinary Bladder Neoplasms , Humans , Adjuvants, Immunologic/therapeutic use , BCG Vaccine/therapeutic use , Immunotherapy , Administration, Intravesical , Urinary Bladder Neoplasms/drug therapy , Biology , Neoplasm Invasiveness , Neoplasm Recurrence, Local/drug therapyABSTRACT
Aging, often considered a result of random cellular damage, can be accurately estimated using DNA methylation profiles, the foundation of pan-tissue epigenetic clocks. Here, we demonstrate the development of universal pan-mammalian clocks, using 11,754 methylation arrays from our Mammalian Methylation Consortium, which encompass 59 tissue types across 185 mammalian species. These predictive models estimate mammalian tissue age with high accuracy (r > 0.96). Age deviations correlate with human mortality risk, mouse somatotropic axis mutations and caloric restriction. We identified specific cytosines with methylation levels that change with age across numerous species. These sites, highly enriched in polycomb repressive complex 2-binding locations, are near genes implicated in mammalian development, cancer, obesity and longevity. Our findings offer new evidence suggesting that aging is evolutionarily conserved and intertwined with developmental processes across all mammals.
Subject(s)
DNA Methylation , Epigenesis, Genetic , Humans , Mice , Animals , DNA Methylation/genetics , Aging/genetics , Longevity/genetics , Mammals/geneticsABSTRACT
BACKGROUND: Using a double blind randomized placebo-controlled trial (Australian New Zealand Clinical Trials Registry: ACTRN12607000518460), we have shown that in a high risk birth cohort, maternal supplementation from 35 weeks gestation until 6 months if breastfeeding and infant supplementation until 2 years with Lactobacillus rhamnosus HN001 (HN001) (6 × 10(9) cfu/day) halved the cumulative prevalence of eczema by age 2 years. Bifidobacterium animalis subsp lactis HN019 (HN019) (9 × 10(9) cfu/day) had no effect. OBJECTIVE: The aim of this study was to investigate the associations of HN001 and HN019 with allergic disease and atopic sensitization among these children at age 4 years, 2 years after stopping probiotic supplementation. METHODS: The presence (UK Working Party's Diagnostic Criteria) and severity SCORing Atopic Dermatitis (SCORAD) of eczema and atopy (skin prick tests) and parent-reported symptoms of asthma and rhinoconjunctivitis were assessed using standard protocols and questions. RESULTS: Four-hundred and seventy-four infants were eligible at birth of whom 425 (90%) participated in this follow-up. The cumulative prevalence of eczema by 4 years (Hazard ratio (HR) 0.57 (95% CI 0.39-0.83)) and prevalence of rhinoconjunctivitis at 4 years (Relative risk 0.38 (95% CI 0.18-0.83)) were significantly reduced in the children taking HN001; there were also nonsignificant reductions in the cumulative prevalence of SCORAD ≥ 10 (HR 0.74 (95% CI 0.52-1.05), wheeze (HR 0.79 (95% CI 0.59-1.07)) and atopic sensitization (HR = 0.72 (95% CI 0.48-1.06)). HN019 did not affect the prevalence of any outcome. CONCLUSIONS AND CLINICAL RELEVANCE: This study showed that the protective effect of HN001 against eczema, when given for the first 2 years of life only, extended to at least 4 years of age. This, together with our findings for a protective effect against rhinoconjunctivitis, suggests that this probiotic might be an appropriate preventative intervention for high risk infants.
Subject(s)
Dietary Supplements , Eczema/prevention & control , Lacticaseibacillus rhamnosus , Probiotics/administration & dosage , Adult , Australia , Breast Feeding , Child, Preschool , Double-Blind Method , Eczema/epidemiology , Female , Humans , Infant , Infant, Newborn , Male , Pregnancy , Pregnancy Trimester, Third , Prevalence , Probiotics/adverse effects , Time FactorsABSTRACT
Gold-coated horizontally aligned carbon nanotube (Au-HA-CNT) substrates were fabricated for surface-enhanced Raman spectroscopy (SERS). The Au-HA-CNT substrates, which are granular in nature, are easy-to-prepare with large SERS-active area. Enhancement factors (EFs) of â¼10(7) were achieved using the Au-HA-CNTs as substrates for rhodamine 6G (R6G) molecules. Maximum enhancement was found when the polarization direction (E-field) of the incident laser beam was parallel to the aligned direction of the HA-CNTs. Simulations using the finite-difference time-domain (FDTD) method were carried out for the granular Au-HA-CNT samples. Enhancement mechanisms and determination of EFs were analyzed. Biological samples, including (13)C- and deuterium (D)-labeled fatty acids and Coccomyxa sp. c-169 microalgae cells, were also measured using this SERS substrate. The limits of detection (LODs) of D- and (13)C-labeled fatty acids on the SERS substrate were measured to be around 10 nM and 20 nM, respectively. Significantly enhanced Raman signals from the microalgae cells were acquired using the SERS substrate.
Subject(s)
Gold/chemistry , Microalgae/chemistry , Microalgae/ultrastructure , Nanotubes, Carbon/chemistry , Nanotubes, Carbon/ultrastructure , Surface Plasmon Resonance/methods , Macromolecular Substances/chemistry , Materials Testing , Molecular Conformation , Particle Size , Surface PropertiesABSTRACT
The animal health system in Australia has evolved over more than 100 years and includes innovative public-private partnership arrangements. The establishment in 1996 of Animal Health Australia (AHA), a not-for-profit company, was a crucial development which formalised arrangements for shared decision-making and funding across both government and industry stakeholders. However, Federal and State governments retain legislative authority for animal health control. Accordingly, all programmes must recognise that the public sector remains an executive arm of government, accountable for its actions. Hence, much effort has been invested in ensuring that the governance arrangements within AHA are lawful and transparent. The Emergency Animal Disease Response Agreement (EADRA) is a very good example of governance arrangements that are sustainably financed, widely available, provided efficiently, without waste or duplication, and in a manner that is transparent and free of fraud or corruption. The benefits of EADRA include certainty and greater transparency of funding; greater efficiency through increased probability of a rapid response to an occurrence of any of 65 diseases; and industry participation in the management and financing of such a response.
Subject(s)
Animal Diseases/prevention & control , Animal Husbandry/organization & administration , Private Sector/organization & administration , Public Sector/organization & administration , Veterinary Medicine/organization & administration , Animal Diseases/epidemiology , Animal Diseases/history , Animal Husbandry/history , Animal Husbandry/standards , Animals , Australia/epidemiology , Disease Outbreaks/history , Disease Outbreaks/prevention & control , Disease Outbreaks/veterinary , Emergencies/epidemiology , Emergencies/history , Emergencies/veterinary , History, 19th Century , History, 20th Century , History, 21st Century , Legislation, Veterinary/history , Private Sector/history , Public Sector/history , Veterinary Medicine/history , Veterinary Medicine/standardsABSTRACT
Through our growing understanding of the molecular mechanisms that drive urothelial transformation and the growth, invasion and metastasis of bladder cancer, we are able to identify an increasingly broad spectrum of molecules and pathways that are suitable for novel targeted therapies. At the same time we are armed with an increasing number of agents designed to disrupt these signaling pathways, and, as these enter the clinical arena in other cancers, the barriers to use in bladder cancer patients decline. Targeted therapy for bladder cancer, however, remains in its infancy, and no major breakthroughs have been achieved. Here we review some of the molecular targets that have been best characterized in bladder cancer, as well as some of the newer targets that appear most promising. We will review the experience up to this point in testing targeted agents against these pathways, and describe some novel agents that have yet to be tested in clinical trials but have shown significant potential in pre-clinical models.
Subject(s)
Antineoplastic Agents/therapeutic use , Molecular Targeted Therapy/methods , Signal Transduction/drug effects , Urinary Bladder Neoplasms/drug therapy , Angiogenesis Inhibitors/therapeutic use , Cell Transformation, Neoplastic , Clinical Trials as Topic , ErbB Receptors/antagonists & inhibitors , Humans , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-met/antagonists & inhibitors , Receptor, Platelet-Derived Growth Factor beta/antagonists & inhibitors , Receptors, Fibroblast Growth Factor/antagonists & inhibitors , Treatment Outcome , Urinary Bladder Neoplasms/genetics , Urinary Bladder Neoplasms/pathology , Vascular Endothelial Growth Factor A/antagonists & inhibitors , Viral Vaccines/therapeutic useABSTRACT
BACKGROUND: In this article, we report the evolution of treatment with increased use of active surveillance for stage I disease as well as risk-adapted chemotherapy for disseminated disease and associated outcomes of testicular seminoma in a contemporary population-based cohort. METHODS: All patients with histologically confirmed seminoma referred from 1999 to 2008 to the British Columbia Cancer Agency or Providence Cancer Center were retrospectively reviewed. Both institutions manage 90% of testicular cancers in their respective area. RESULTS: A total of 649 patients were included. Clinical stage (CS) distribution: CSI/II/III n=545/87/17. For CSI, there was a progressive and marked decrease in the utilization of prophylactic radiation (RT), and corresponding increase in the use of active surveillance. No deaths related to seminoma were reported in CSI patients. CSII or CSIII patients received RT or International Germ Cell Cancer Collaborative Group (IGCCCG) risk-appropriate chemotherapy with 101 of 104 patients being in long-term remission and 3 patients dying from treatment complications. For the entire seminoma population, <1% of patients died of seminoma or treatment after a median follow-up of 47 months (range 2-130 months). CONCLUSIONS: Progressive application of policies of active surveillance and earlier initiation of IGCCCG risk-adapted chemotherapy result in nearly universal control for all patients presenting with seminoma while reducing the burden of treatment.
Subject(s)
Seminoma/therapy , Testicular Neoplasms/therapy , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bleomycin/administration & dosage , Bleomycin/therapeutic use , Cisplatin/administration & dosage , Cisplatin/therapeutic use , Combined Modality Therapy , Etoposide/administration & dosage , Etoposide/therapeutic use , Follow-Up Studies , Humans , Male , Middle Aged , Orchiectomy , Radiotherapy, Adjuvant , Retrospective Studies , Seminoma/pathology , Testicular Neoplasms/pathology , Treatment Outcome , Watchful WaitingABSTRACT
BACKGROUND: Orally administered milk fat enriched in conjugated linoleic acid (CLA) and trans-vaccenic acid (VA) ('enriched milk fat'), produced by supplementing the diet of pasture-fed cows with fish and sunflower oil, has been shown previously to suppress the development of allergic airway disease in mice. OBJECTIVE: To investigate whether topical or oral application of enriched milk fat and its two major fatty acids cis-9, trans-11 CLA (c9,t11-CLA) and VA inhibit allergic dermatitis in mice. METHODS: Allergic dermatitis was induced in C57BL/6 mice by epicutaneous sensitization of tape-stripped skin with ovalbumin (OVA). Enriched milk fat and its two major fatty acids were either topically applied to the OVA-sensitized skin, or orally fed to mice by supplementation of the diet. Blood and skin tissues were collected for analysis after the third skin sensitization. RESULTS: Both topical and oral administration of enriched milk fat and its two major fatty acids led to significant suppression of allergic dermatitis as evidenced by reduced clinical and histological scores of affected skins, infiltration of inflammatory cells, and circulating allergen-specific IgE levels, compared with treatment with normal milk fat or the base control diet. C9,t11-CLA and VA individually inhibited multiple facets of allergic dermatitis when topically applied, and their combination produced a strong additive effect. CONCLUSION AND CLINICAL RELEVANCE: Enriched milk fat, and its two major fatty acids c9,t11-CLA and vaccenic acid attenuate allergic dermatitis in mice.